Pharmalittle: Icahn dealt setbacks in bid to derail Cigna deal for Express Scripts; Pfizer suit against J&J proceeds Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. By Ed Silverman Aug. 13, 2018 Reprints Tags drug pricingfinancepharmaceuticalspolicySTAT+Vaccines STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. [email protected] GET STARTED Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that familiar routine of meetings, deadlines, and the like has returned. You knew this would happen, even if it is high vacation season. After all, the world is still spinning. So please join us as we fire up the coffee kettle to brew some cups of stimulation and hunker down for another busy day. Toward that end, we have assembled some tidbits to help you along. Hope your day is smashing and do keep in touch …Glass Lewis recommended Cigna (CI) shareholders vote in favor of the proposed $52 billion acquisition of Express Scripts (ESRX), the second proxy advisory firm to support the deal, Reuters writes. Carl Icahn, who owns shares in Cigna, opposes the deal, but hedge fund Glenview Capital Management, which also has a stake in the health insurer, has backed the purchase. On Friday, Institutional Shareholder Services also extended support. Icahn, who has a 0.56 percent stake in Cigna, cited regulatory hurdles and a growing threat from Amazon as reasons to vote it down. Log In | Learn More Alex Hogan/STAT About the Author Reprints Pharmalot What’s included? @Pharmalot Ed Silverman Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED What is it?